HSBC Holdings
ALNY icon

HSBC Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

HSBC Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.8M Buy
120,600
+6,000
+5% +$1.81M 0.01% 618
2026
Q1 		$37.8M Hold
114,600
– – 0.02% 588
2025
Q4 		$46M Buy
+114,600
New +$50.7M 0.02% 514

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HSBC Holdings's ALNY Position: Q2 2026 in Review

HSBC Holdings increased its Alnylam Pharmaceuticals (ALNY) stake by 29% in Q2 2026, buying an estimated $7.74M and bringing the position to 115,279 shares worth $34.6M. The position accounts for 0.01% of the portfolio, ranked #628.

HSBC Holdings first reported a position in ALNY in Q4 2014 and has held it in 44 quarters since. The position peaked at $35.7M in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • HSBC Holdings held 115,279 shares of Alnylam Pharmaceuticals worth $34.6M as of Q2 2026.
  • HSBC Holdings bought 25,660 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $7.74M.
  • Alnylam Pharmaceuticals made up 0.01% of HSBC Holdings's portfolio in Q2 2026, its #628 holding.
  • HSBC Holdings first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 44 quarters since.
  • HSBC Holdings's Alnylam Pharmaceuticals position peaked at $35.7M in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.